Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Matthias Steiert

Matthias Steiert

Los Gatos Pharmaceuticals, USA

Title: LPG-1, a novel anti-tumor prodrug-conjugate nanoparticle formulation overcoming severe side effects of existing treatment

Biography

Biography: Matthias Steiert

Abstract

A novel proprietary product is under development that overcomes existing challenges based on the compound SN-38 and its parent compounds Topotecan and Irinotecan. It overcomes the short tumor half-life (Topotecan and Irinotecan) and enterohepatic/GI toxicitiy (SN-38). A chemical modification of SN-38 resulting in a product that will be metabolized into the active compound combined with a nanoparticle formulation using PLGA and other block-copolymers has demonstrated improved efficacy in vitro and in vivo as compared to parent camptothecins. Increased tumor concentrations and duration of exposure as compared to native SN-38 should, therefore, be achievable via passive targeting resulting in potentially improved safety profile by reducing entero-hepatic recirculation. Target indication chemotherapy of solid tumors of this product is colorectal cancer, NSCLC, and others.